Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Many patients on new HCV medications at risk of drug-drug interactions

Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.

Published
23 December 2015
From
Medscape (requires free registration)
Scientists reveal new phase of HIV infection

A new life cycle stage in HIV infection has been identified thanks to a novel technique they developed to take images of intact infected cells. Researchers have shown that this phase of infection, dubbed intra-nuclear migration, relies on the human protein CPSF6 to guide the virus through the host cell's nucleus and position it at active genes where it prefers to make its home.

Published
19 December 2015
From
Science Daily
Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare

Bristol-Myers Squibb Company today announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development. The agreements with ViiV Healthcare do not impact Bristol-Myers Squibb’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla. Bristol-Myers Squibb remains committed to the commercialization of these products and to those patients who rely on these medicines.

Published
18 December 2015
From
Bristol-Myers Squibb press release
Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model

The superior safety of the tenofovir analogue tenofovir alafenamide fumarate (TAF) over tenofovir disoproxil fumarate (TDF) would justify a price premium of at most $1,010 per patient per

Published
18 December 2015
By
Michael Carter
Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings

Virologically suppressive first-line antiretroviral treatment with a two-drug regimen of dolutegravir (Tivicay) and lamivudine would be highly cost effective and could save US health systems

Published
17 December 2015
By
Michael Carter
NIH drops special 10% set-aside for AIDS research

In a major shakeup for the HIV/AIDS research community, the National Institutes of Health (NIH) today announced it will no longer support setting aside a fixed 10% of its budget—or $3 billion this year—to fund research on the disease. The agency also plans to reprogram $65 million of its AIDS research grant funding this year to focus more sharply on ending the epidemic.

Published
15 December 2015
From
Science
Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Preliminary data suggest adenoviral delivery method superior for immune stimulation and control of viral load in the absence of antiretroviral therapy (ART); two of three subjects remain off ART for more than one year.

Published
14 December 2015
From
Sangamo Biosciences press release
Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued

Drug resistance acquired in rare cases of HIV infection during treatment with pre-exposure prophylaxis (PrEP) rapidly disappears once medication is discontinued, investigators report in AIDS. Use of ultra-sensitive tests

Published
14 December 2015
By
Michael Carter
Study: Protease Inhibitor Monotherapy Does Not Limit Future Treatment Options

A recent study published in The Lancet HIV provides evidence that HIV maintenance therapy with a provider-selected boosted protease inhibitor (PI) regimen does not increase the risk of drug resistance and thus preserves future treatment options. But questions remain as to whether PI-monotherapy could be a clinically useful and relevant long-term HIV maintenance strategy.

Published
10 December 2015
From
BETA blog
South African Medicines Agency approves PrEP

The South African Medicines Control Council (MCC) has approved PrEP. So far it has issued a brief statement, saying that on 28 November it "Approved the use of the fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine to include pre-exposure prophylaxis of HIV(also referred to as PrEP)." The MCC names the separate drugs rather than Truvada, as South Africans take generic versions of the drugs made on licence locally. The MCC does not recommend criteria for PrEP access or name specific populations but instead soliticts applications from organisations that wish to provide PrEP. Its one stipulation is that, since using the drugs for prevention is a new field, records of adverse events in people offered PrEP should be kept by providers.

Published
08 December 2015
From
South African MCC

Filter by country